GlobeNewswire

LeoVegas strengthens Group Management team and increases focus on LeoSafePlay and sustainability

Dela

LeoVegas Group is making several changes to its Group Management with the aim to optimise work on driving the Company's strategic agenda for sustainability and the ongoing journey of growth, with a further intensified focus on responsible gaming and LeoSafePlay.

New COO in Malta
Richard Woodbridge has been recruited as LeoVegas' new Chief Operating Officer (COO) and will have overarching responsibility for operations at LeoVegas' offices in Malta. Richard will assume his new role by 7 January 2019 at the latest and will be a member of LeoVegas' Group Management.

"LeoVegas is the leading GameTech company in the industry, and I have a passion for working with fast-growing tech companies," says Richard Woodbridge. "I am looking forward to being part of LeoVegas' continued journey of growth and optimising LeoVegas' operations, with sustainability as a guiding principle."

Richard Woodbridge joins LeoVegas from his role as COO of Ellos Group, and prior to this he held a corresponding position at the fast-growing e-commerce company Nelly.com.

Gustaf Hagman, Group CEO, comments: "Richard's background and personality are a perfect fit for LeoVegas as we continue to focus on growth and sustainability. Overarching responsibility for operations is growing increasingly important now that we have some 750 employees, of whom 400 are based in Malta. LeoVegas is a data-driven company in which we use a number of key metrics to further improve ourselves and increase our productivity. This has become even more crucial as we have begun acquiring companies and working with multiple brands. With his experience and capacity Richard will make a major contribution to our growth going forward."

LeoVegas' current COO, Marcus Nylén, will continue serving in that role in Malta through autumn 2018 until Richard takes office. Due to Marcus and Louise Nyléns relationship as closely related persons, Marcus will leave the Group Management when Richard joins to focus entirely on his role as head of LeoVegas' global expansion.

New Deputy CEO
Louise Nylén will assume the newly created role of Deputy CEO of LeoVegas Mobile Gaming Group, stationed in Stockholm. Louise was formerly Chief Marketing Officer (CMO) of LeoVegas. In her role as Deputy CEO she will work side by side Group CEO Gustaf Hagman with strategic issues such as sustainability and value-creating projects, among other things. Louise will assume her new position in the Company today the 10th of July.

"In my new role as Deputy CEO I will have a broader platform to work from, which will enable me to promote sustainability, growth and value for the Company," comments Louise Nylén. "I am very excited to have this trust and opportunity to continue contributing to LeoVegas' rapid development."

"Louise has been with LeoVegas and based in Malta since 2013, holding the position as CMO since 2015," continues Gustaf Hagman, Group CEO of LeoVegas Mobile Gaming Group. "In that role she has built up a data-driven and effective market team that is responsible for LeoVegas' customer acquisition and global brand-building. Much of the approach in this work can be used across a broader front in the Company. Louise has also played a key role in building our company culture and driving sustainability, and I look forward to work with Louise and all other employees to achieve our financial targets for 2020 of at least EUR 600m in revenue and at least EUR 100m in EBITDA.

Louise's former role as CMO will be broken up into several roles in Malta and will thereby be phased out.

LeoSafePlay - new business unit for next generation responsible gaming system
Rikard Ljungman is leaving his position as Chief Commercial Officer (CCO) as well as LeoVegas' Group Management to focus entirely on responsible gaming and LeoSafePlay. LeoSafePlay will be run as a separate business unit in order to create the best conditions for the next generation responsible gaming system based on machine learning.  Richard Woodbridge will take over Rikard Ljungman's CCO-related duties in Malta.

"Rikard was one of the initiative-takers behind LeoSafePlay, and with his strong product background, including as CPO for the software company Episerver, he has the exact right expertise to take the next step to make LeoVegas the leader in responsible gaming technology and strengthen our position as a GameTech company," comments Gustaf Hagman, Group CEO.

For further information, please contact :

Gustaf Hagman, Group CEO and co-founder: +46-(0)8-410 367 66, gustaf.hagman@leovegas.com
Philip Doftvik, Head of Investor Relations: +46-(0)73-512 07 20, philip.doftvik@leovegas.com

About the LeoVegas mobile gaming group
LeoVegas' passion is "Leading the way into the mobile future". LeoVegas is Sweden's premier GameTech company and is at the forefront of using state-of-the-art technology for mobile gaming. In 2017 the company passed the threshold for being classified as a unicorn, i.e., a start-up valued at more than USD 1 billion. A large part of this success can be credited to an extreme product and technology focus coupled with effective and data-driven marketing. Technology development is conducted in Sweden, while operations are based in Malta. LeoVegas offers casino, live casino and sports betting, and operates two global and scalable brands - LeoVegas and Royal Panda - as well as a local, multibrand operator collectively referred to as Rocket X. The company's shares are listed on Nasdaq Stockholm. For more about LeoVegas, visit www.leovegasgroup.com .




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LeoVegas AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum